<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">QUINAPRIL HYDROCHLORIDE</span><br/>(quin'a-pril)<br/><span class="topboxtradename">Accupril<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin-converting enzyme (ace) inhibitor</span><br/><b>Prototype: </b>Enalapril<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg, 40 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Potent, long-acting second-generation ACE inhibitor that lowers BP by interrupting the conversion sequences initiated by renin
         to form angiotensin II; a vasoconstrictor. Inhibition of ACE also decreases circulating aldosterone, a secretory response
         to angiotensin II stimulation. Reduces pulmonary capillary wedge pressure, systemic vascular resistance, and mean arterial
         pressure, with concurrent increases in cardiac output, cardiac index, and stroke volume.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers BP by producing vasodilation. Effective in the treatment of CHF because improves cardiac indicators.</p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderate hypertension, CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to quinapril or other ACE inhibitors; pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal insufficiency, autoimmune disease, volume-depleted patients, renal artery stenosis, neutropenia.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, CHF</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1020 mg q.d., may increase up to 80 mg/d in 12 divided doses<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 2.55 mg q.d.<br/><br/><span class="indicationtitle">Renal Insufficiency</span><br/><span class="rdroute"></span> Cl<sub>cr</sub> 3060 mL/min: 5 mg/q.d. initially; Cl<sub>cr</sub> </td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Discontinue diuretics 23 d before initiation of quinapril. Do <small>NOT</small> exceed initial dose of 5 mg if diuretics cannot be discontinued.
         </li>
<li>Store at 15°30° C (59°86° F) and protect from moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Edema, hypotension. <span class="typehead">CNS:</span> Dizziness, fatigue, headache. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea. <span class="typehead">Hematologic:</span> Eosinophilia, neutropenia. <span class="typehead">Metabolic:</span> Hyperkalemia, proteinuria. <span class="typehead">Respiratory:</span> Cough. <span class="typehead">Body as a Whole:</span>
<span class="speceff-life">Angioedema</span>, myalgia. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May increase <span class="alt">BUN</span> or <span class="alt">serum creatinine.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">potassium-sparing diuretics</span> may increase risk of hyperkalemia. May elevate serum <b>lithium</b> levels, resulting in <b>lithium</b> toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Onset:</span> 1 h. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Duration:</span> Up to 24 h. <span class="typehead">Distribution:</span> 97% bound to plasma proteins; crosses placenta; not known if distributed into breast milk. <span class="typehead">Metabolism:</span> Extensively metabolized in liver to its active metabolite, quinaprilat. <span class="typehead">Elimination:</span> 5060% excreted in urine, primarily as quinaprilat; 30% excreted in feces. <span class="typehead">Half-Life:</span> 2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP at time of peak effectiveness, 24 h after dosing, and at end of dosing interval just before next dose.</li>
<li>Report diminished antihypertensive effect toward end of dosing interval. Inadequate trough response may indicate need to divide
            daily dose.
         </li>
<li>Monitor for first-dose hypotension, especially in salt- or volume-depleted clients.</li>
<li>Lab tests: Monitor BUN and serum creatinine periodically. Increases may necessitate dose reduction or discontinuation of drug.
            Monitor serum potassium values.
         </li>
<li>Observe for S&amp;S of hyperkalemia (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue quinapril and report S&amp;S of angioedema (e.g., swelling of face or extremities, difficulty breathing or swallowing)
            to physician.
         </li>
<li>Maintain adequate fluid intake and avoid potassium supplements or salt substitutes unless specifically prescribed by physician.</li>
<li>
            							Note: A high-fat meal may lessen drug's absorption.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>